Immunohistochemical (IHC) detection of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) is the foundation of clinical subtyping of breast cancer since it selects targets for endocrine or HER2-targeted therapy [1–3]. This evidence concerns the gene ESR1 and breast cancer.